Advertisement

RMSF and Serious Tick-Borne Illnesses (Lyme, Ehrlichiosis, Babesiosis and Tick Paralysis)

  • Maureen McCollough
Chapter

Abstract

Rocky Mountain spotted fever (RMSF) and other tick-borne illnesses, a burden predominantly in the summer season, produce symptoms ranging from fever to paralysis. Although often benign, sequela can range from chronic arthritis to neurologic or cardiac illness. Especially in the areas of the North America where tick-borne illnesses are more prevalent, tick-borne illnesses require vigilance on the provider’s part to inquire about recent outdoor activity. Prevention is paramount including the use of protective clothing and tick repellent.

Keywords

Babeosis Borrelia burgdorferi Doxycycline Ehrlichiosis Erythema migrans Lyme disease Rickettsia rickettsia Rocky Mountain spotted fever Tick-borne illness Tick paralysis 

References

  1. 1.
    Biggs HM, Behravesh CB, Bradley KK, et al. Centers for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial diseases: rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis – United States. MMWR. 2016;65(2):1–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Marshall GS, Stout GG, Jacobs RF, et al. Antibodies reactive to Rickettsia rickettsii among children living in the southeast and south central regions of the United States. Arch Pediatr Adolesc Med. 2003;157:443–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Openshaw JJ, Swerdlow DL, Krebs JW, et al. Rocky Mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg. 2010;83:174–82.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dahlgren FS, Mandel EJ, Krebs JW, et al. Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007. Am J Trop Med Hyg. 2011;85:124–31.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Buckingham SC. Tick-borne diseases of the USA: ten things clinicians should know. J Infect. 2015;71:S88–96.CrossRefPubMedGoogle Scholar
  6. 6.
    Dworkin MS, Shoemaker PC, Anderson DE. Tick paralysis: 33 human cases in Washington State, 1946-1996. Clin Infect Dis. 1999;29(6):1435–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Edlow JA, McGillicuddy DC. Tick paralysis. Infect Dis Clin N Am. 2008;22:397–413.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366:2397–407.CrossRefPubMedGoogle Scholar
  10. 10.
    Sexton DJ, McClain MT. Clinical manifestations and diagnosis of Rocky Mountain spotted fever. UpToDate May 18, 2016.Google Scholar
  11. 11.
    Mukkada S, Buckingham S. Recognition of and prompt treatment for tick-borne infections in children. Infect Dis Clin N Am. 2015;29:539–55.CrossRefGoogle Scholar
  12. 12.
    Woods CR. Rocky Mountain spotted fever in children. Pediatr Clin N Am. 2013;60:455–70.CrossRefGoogle Scholar
  13. 13.
    Helmick CG, Bernard KW, D’Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis. 1984;150:480.CrossRefPubMedGoogle Scholar
  14. 14.
    Sexton DJ, Corey GR. Rocky Mountain “spotless” and “almost spotless” fever: a wolf in sheep’s clothing. Clin Infect Dis. 1992;15:439–48.CrossRefPubMedGoogle Scholar
  15. 15.
    Buckingham SC, Marshall GS, Schutze GE, et al. Clinical and laboratory features of Rocky Mountain spotted fever in children. J Pediatr. 2007;150:180–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen LF, Sexton DJ. What’s new in Rocky Mountain spotted fever? Infect Dis Clin N Am. 2008;22:415–43.CrossRefGoogle Scholar
  17. 17.
    Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Rocky Mountain spotted fever In Red book: 2012 report of the committee on infectious diseases. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012. p. 623–625.Google Scholar
  18. 18.
    Feder HM Jr. Lyme disease in children. Infect Dis Clin N Am. 2008;22:315–26.CrossRefGoogle Scholar
  19. 19.
    Steere AC, Sikand VK. The presenting manifestations of Lyme disease and outcomes of treatment. N Engl J Med. 2003;348:2472–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Shapiro E. Lyme disease: clinical manifestations in children. UpToDate June 26, 2016.Google Scholar
  21. 21.
    Hu L. Treatment of Lyme disease. UpToDate June 19, 2017Google Scholar
  22. 22.
    Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from ixodes ticks. Clin Microbiol Rev. 2006;19:708.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Steere AC, McHugh G, Suarez C, et al. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003;36:1078.CrossRefPubMedGoogle Scholar
  24. 24.
    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089–134.CrossRefPubMedGoogle Scholar
  25. 25.
    Nichols Heitman K, Dahlgren FS, Drexler NA, et al. Increasing incidence of ehrlichiosis in the United States: a summary of national surveillance of Ehrlichia chaffeensis and Ehrlichia ewingii infections in the United States, 2008-2012. Am J Trop Med Hyg. 2016;94:52.CrossRefPubMedGoogle Scholar
  26. 26.
    Sexton DJ, McClain MT. Human ehrlichiosis and anaplasmosis. UpToDate Aug 15, 2016.Google Scholar
  27. 27.
    Ratnasamy N, Everett ED, Roland WE, et al. Central nervous system manifestations of human ehrlichiosis. Clin Infect Dis. 1996;23:314.CrossRefPubMedGoogle Scholar
  28. 28.
    Buckingham SC. Tick-borne diseases in children: epidemiology, clinical manifestations and optimal treatment strategies. Paediatr Drugs. 2005;7:163–76.CrossRefPubMedGoogle Scholar
  29. 29.
    Gelfand JA, Vannier EG. Clinical manifestations, diagnosis, treatment and prevention of babesiosis. UpToDate Mar, 2017.Google Scholar
  30. 30.
    CDC Babesiosis. Surveillance for Babesiosis – United States 2014, Annual Summary reported Feb 29, 2016. https://www.cdc.gov/parasites/babesiosis/resources/babesiosis_surveillance_summary_2016.pdf.
  31. 31.
    Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes tick-borne pathogens: ecological, epidemiological and clinical consequences. Trends Parasitol. 2016;32:30–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Sanchez E, Vannier E, Wormser GP, et al. Treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767–77.CrossRefPubMedGoogle Scholar
  33. 33.
    CDC Babesiosis. Treatment DPDx Laboratory identification of parasitic diseases of public health concern. Updated Nov 29, 2013. https://www.cdc.gov/dpdx/babesiosis/tx.html.
  34. 34.
    Mareedu N, Schotthoefer A, et al. Risk factors for severe infection, hospitalization, and prolonged antimicrobial therapy in patients with babesiosis. Am J Trop Med Hyg. 2017;97(4):1218–25.CrossRefPubMedGoogle Scholar
  35. 35.
    Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. West Nile virus infection: a new acute paralytic illness. Neurology. Jul 8 2003;61(1):55–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Jackson AC. Leg weakness associated with Powassan virus infection–Ontario. Can Dis Wkly Rep. Jun 17 1989;15(24):123–4.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Maureen McCollough
    • 1
    • 2
  1. 1.David Geffen School of Medicine at UCLA, Department of Emergency MedicineLos AngelesUSA
  2. 2.Oliveview-UCLA Medical CenterSylmarUSA

Personalised recommendations